SCHEMBL1496970

SCHEMBL1496970

CN(C)CCN(Cc1ccc(C(=O)Nc2cscc2N)nc1)C(=O)NC1CC1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.39
PDCD1 Q15116 6/20 0.37
CD274 Q9NZQ7 6/20 0.37
ACVR1 Q04771 2/20 0.36
ROCK1 Q13464 2/20 0.36
ROCK2 O75116 2/20 0.35
HTR5A P47898 2/20 0.34
SMYD3 Q9H7B4 1/20 0.34
HDAC3 O15379 2/20 0.34
HDAC1 Q13547 2/20 0.34
HDAC2 Q92769 2/20 0.34
HDAC10 Q969S8 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
CRHR1 P34998 1/20 0.34
MAPK13 O15264 1/20 0.33
MAPK12 P53778 1/20 0.33
MAPK11 Q15759 1/20 0.33
MAPK14 Q16539 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1496884 0.96 GAA (0.43) GAAPDCD1CD274ACVR1ROCK1
SCHEMBL1496938 0.91 GAA (0.50) GAAPDCD1CD274ACVR1ROCK1
SCHEMBL4228687 0.88 HDAC1 (0.46) GAAPDCD1CD274ROCK1HDAC3
SCHEMBL1497176 0.88 PDCD1 (0.39) PDCD1CD274ROCK1ROCK2HDAC3
SCHEMBL1496903 0.86 PDCD1 (0.38) PDCD1CD274ACVR1ROCK1ROCK2
SCHEMBL1482493 0.86 PDCD1 (0.41) PDCD1CD274ROCK1ROCK2HDAC3
SCHEMBL1497163 0.85 GAA (0.36) GAAPDCD1CD274ROCK1ROCK2
SCHEMBL1482611 0.85 PDCD1 (0.38) PDCD1CD274ACVR1ROCK1ROCK2
SCHEMBL1496872 0.85 PDCD1 (0.38) PDCD1CD274ROCK1ROCK2HDAC3
SCHEMBL4224190 0.85 HDAC1 (0.45) GAAPDCD1CD274ACVR1ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8288380-B2 Thiophenediamine derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-10-16 US disclosed
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-08-09 US disclosed
EP-2292611-B1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO LTD (JP) 2012-07-25 EP disclosed
US-8198271-B2 Thiophenediamine derivative having urea structure SANTEN PHARMACEUTICAL CO., LTD. (JP) 2012-06-12 US disclosed
US-20110077244-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE SANTEN PHARMACEUTICAL CO., LTD. (JP) 2011-03-31 US disclosed
EP-2292611-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2011-03-09 EP disclosed
EP-2292611-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE Santen Pharmaceutical Co., Ltd (JP) 2011-03-09 EP disclosed
WO-2009142321-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE 参天製薬株式会社 (JP) 2009-11-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120202808-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE CBR1, NAT1, PRMT1 GAA 4745/4885PDCD1 4160/4885CD274 4096/4885
US-20110077244-A1 NOVEL THIOPHENEDIAMINE DERIVATIVE HAVING UREA STRUCTURE HNMT, HRH4, CHRM1 GAA 2968/4885PDCD1 4547/4885CD274 4718/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.